Breast Cancer Trial, Recruiting (NCT07046689)

Breast Cancer Trial, Recruiting NCT07046689 Sponsor: The First Affiliated Hospital of Xiamen University Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07046689 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People with breast cancer that has spread to other parts of the body (metastatic), confirmed by laboratory testing of tissue or cells, and who have already received some form of treatment for this cancer
People who have at least one tumour that can be measured using standard imaging criteria (known as RECIST 1.1)
People who are willing to have a series of specialised nuclear medicine scans (called 68Ga-MY6349 PET/CT scans) before and during a type of targeted cancer treatment called a Trop2-ADC therapy
People who are relatively well and able to carry out daily activities, based on a standard health scale rated 0 or 1 (confirm with trial site)
People who are able to sign a written consent form agreeing to participate in the trial

Who may not be able to join:

People whose liver or kidneys are not functioning well
People whose doctors estimate they have fewer than 3 months to live

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 86 18818350620

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07046689

Sponsor: The First Affiliated Hospital of Xiamen University

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: 86 18818350620

More information: https://clinicaltrials.gov/study/NCT07046689

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People with breast cancer that has spread to other parts of the body (metastatic), confirmed by laboratory testing of tissue or cells, and who have already received some form of treatment for this cancer
People who have at least one tumour that can be measured using standard imaging criteria (known as RECIST 1.1)
People who are willing to have a series of specialised nuclear medicine scans (called 68Ga-MY6349 PET/CT scans) before and during a type of targeted cancer treatment called a Trop2-ADC therapy
People who are relatively well and able to carry out daily activities, based on a standard health scale rated 0 or 1 (confirm with trial site)
People who are able to sign a written consent form agreeing to participate in the trial

Who may not be able to join:

People whose liver or kidneys are not functioning well
People whose doctors estimate they have fewer than 3 months to live

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The First Affiliated Hospital of Xiamen University

Registry

ClinicalTrials.gov

Start date

1 November 2024

Est. completion

31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The predictive value of series 68Ga-MY6349 PET/CT in patients with breast cancer who received Trop2-ADC therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov